Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ, Kim JJ, Pyne D, Travas A, Ambalavanan A, Kimura S, Deininger MW, Kim JW, Kim DDH. Han HJ, et al. Among authors: kim ddh, kim jj, kim jw. Leukemia. 2024 Feb;38(2):412-415. doi: 10.1038/s41375-023-02122-5. Epub 2023 Dec 28. Leukemia. 2024. PMID: 38155246 No abstract available.
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, Kim DDH. Park JH, et al. Among authors: kim ddh, kim hj, kim sh, kim jw. Leukemia. 2019 Jun;33(6):1439-1450. doi: 10.1038/s41375-018-0321-8. Epub 2018 Dec 16. Leukemia. 2019. PMID: 30555164 Free PMC article.
Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors.
Jang HJ, Woo YM, Naka K, Park JH, Han HJ, Kim HJ, Kim SH, Ahn JS, Kim T, Kimura S, Zarabi S, Lipton JH, Minden MD, Jung CW, Kim HJ, Kim JW, Kim DDH. Jang HJ, et al. Among authors: kim ddh, kim hj, kim sh, kim t, kim jw. Cancers (Basel). 2021 Nov 4;13(21):5543. doi: 10.3390/cancers13215543. Cancers (Basel). 2021. PMID: 34771705 Free PMC article.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Among authors: kim ddh, kim dw. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure.
Linn SM, Novitzky-Basso I, Patriquin C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Barth D, Kim DDH. Linn SM, et al. Among authors: kim ddh. Leuk Res. 2023 Nov;134:107387. doi: 10.1016/j.leukres.2023.107387. Epub 2023 Sep 9. Leuk Res. 2023. PMID: 37734221
135 results